How to Get Lantus (Insulin Glargine) in Delaware

What Is Lantus and Why Is It Prescribed?

Lantus is a long-acting basal insulin analog manufactured by Sanofi. It lowers blood glucose by stimulating peripheral glucose uptake and suppressing hepatic glucose production over approximately 24 hours with no pronounced peak. The FDA approved the original Lantus formulation in April 2000, and the label specifies use in adults with type 2 diabetes and patients aged 6 years and older with type 1 diabetes. [1]

The landmark ORIGIN trial (N=12,537) published in the New England Journal of Medicine in 2012 showed that insulin glargine titrated to a fasting glucose target of 95 mg/dL or less did not increase major cardiovascular events compared with standard care over a median follow-up of 6.2 years (hazard ratio 1.02 to 95% CI 0.94 to 1.11). [2] That finding gave clinicians confidence that long-term glargine therapy carries an acceptable cardiovascular risk profile.

A 2019 Cochrane systematic review of basal insulin analogs (including glargine) in type 2 diabetes found that glargine reduced HbA1c by roughly 0.9 to 1.2 percentage points from baseline in trials lasting 24 to 52 weeks. [3] The American Diabetes Association 2024 Standards of Care list basal insulin as a foundational option when non-insulin agents fail to achieve glycemic targets. [4]

Standard dosing begins at 0.1 to 0.2 units/kg/day subcutaneously at the same time each night. Titration occurs in 2-unit increments every three days until fasting glucose reaches the individualized target, typically 80 to 130 mg/dL per ADA guidance. [4]

Who Can Prescribe Lantus in Delaware?

Any licensed prescriber with authority to write Schedule V and non-scheduled prescription medications in Delaware can prescribe Lantus. In practice, that means MDs, DOs, nurse practitioners, and physician assistants.

Delaware granted nurse practitioners full practice authority effective July 2016 under Delaware Code Title 24, Chapter 19. NPs may prescribe, dispense, and administer medications, including insulin, without a physician collaboration agreement. [5] Physician assistants in Delaware operate under a delegation agreement with a supervising physician but retain independent prescriptive authority for most non-controlled agents, including insulin glargine. [6]

Endocrinologists and primary care physicians remain the most common prescribers. The American Association of Clinical Endocrinology 2022 Diabetes Consensus Statement recommends basal insulin initiation when HbA1c exceeds 9% at diagnosis or when two or more oral agents fail to control glucose adequately. [7] Internists and family medicine physicians regularly initiate and manage Lantus therapy without subspecialty referral.

Certified diabetes care and education specialists (CDCES) in Delaware can adjust insulin doses under a collaborative practice agreement with a supervising physician or NP, although they cannot independently write a new prescription.

How to Get a Lantus Prescription in Delaware: Step-by-Step

Getting Lantus in Delaware follows a predictable sequence regardless of whether the visit is in-person or via telehealth.

Step 1: Schedule a clinical visit. Book an appointment with your primary care physician, endocrinologist, or a Delaware-licensed telehealth provider. The visit can be synchronous audio-video under Delaware telehealth regulations adopted under Senate Bill 276 (2018). [8]

Step 2: Present your diabetes diagnosis documentation. Bring (or upload) recent HbA1c results, fasting glucose logs, and any prior diabetes medication history. A HbA1c of 6.5% or higher on two separate tests satisfies ADA diagnostic criteria. [4]

Step 3: Discuss dosing and injection technique. Your clinician will calculate a starting dose, counsel on hypoglycemia recognition, and confirm your preferred injection sites (abdomen, thigh, or upper arm).

Step 4: Receive the electronic prescription. Delaware participates in the national PDMP (Prescription Drug Monitoring Program) network. Clinicians send e-prescriptions directly to your pharmacy of choice through the SureScripts network.

Step 5: Obtain insurance pre-authorization if required. Many commercial plans and Delaware Medicaid require prior authorization before covering Lantus. See the PA section below.

Step 6: Fill at a Delaware-licensed pharmacy. Most major chains (CVS, Walgreens, Walmart, Rite Aid) stock Lantus SoloStar pens and vials. Rural patients may use mail-order pharmacies licensed by the Delaware Board of Pharmacy.

Telehealth Options for Lantus in Delaware

Telehealth prescribing of insulin glargine is fully permitted in Delaware. The state's telehealth parity law requires commercial insurers to reimburse telehealth visits at the same rate as in-person visits for covered services, including diabetes management. [8]

Several national telehealth platforms hold Delaware prescriber licenses and offer endocrinology or internal medicine consultations within 24 to 48 hours. HealthRX providers practice under Delaware licensure and can evaluate, diagnose, and prescribe Lantus during a single synchronous video visit for established diabetic patients who have recent labs available.

The Federation of State Medical Boards' 2020 telemedicine guidelines, adopted in principle by the Delaware Board of Medical Licensure, specify that a valid prescriber-patient relationship can be established through a real-time audio-video encounter without a prior in-person visit. [9] That means a Delaware resident who has never seen a particular telehealth provider in person can still receive a new Lantus prescription after an appropriate clinical evaluation.

HealthRX Telehealth Lantus Access Framework for Delaware Patients:

1. Complete asynchronous intake form with HbA1c, fasting glucose, current medications, and insurance information.
2. Synchronous video visit (typically 20 to 30 minutes) with a Delaware-licensed MD or NP.
3. E-prescription transmitted to your chosen Delaware pharmacy or mail-order pharmacy within 2 hours of visit completion.
4. Follow-up glucose titration check at 2 weeks via asynchronous messaging or brief video call.
5. Prior authorization submission handled by HealthRX clinical staff if the patient's plan requires PA.

What Labs Are Needed Before Starting Lantus?

A full pre-prescription lab panel is not legally required, but clinical guidelines recommend specific baseline tests before initiating or continuing basal insulin therapy.

The ADA 2024 Standards of Care recommend obtaining HbA1c, a basic metabolic panel (BMP) including serum creatinine and electrolytes, a urinary albumin-to-creatinine ratio, and a lipid panel at the time of diabetes diagnosis or before initiating insulin. [4] A TSH is standard for type 1 patients because autoimmune thyroid disease co-occurs in roughly 17 to 30% of type 1 cases. [10]

For telehealth visits, labs drawn within the preceding 90 days generally satisfy clinical requirements. Patients who do not have recent results may visit any LabCorp or Quest Diagnostics location in Delaware. Most results are available within 24 hours, allowing the prescriber to complete the evaluation the following day.

Renal function matters because significant insulin accumulation can occur when the glomerular filtration rate falls below 30 mL/min/1.73m2, requiring dose reduction per the FDA label. [1] The label notes no pharmacokinetic studies have been conducted in patients with hepatic impairment, so liver function tests are prudent for patients with known liver disease. [1]

Continuous glucose monitoring (CGM) data, when available, provides richer titration guidance than finger-stick logs alone. The ADA endorses CGM use for all insulin-using patients as of the 2024 Standards. [4]

Prior Authorization for Lantus Under Delaware Medicaid and Commercial Plans

Delaware Medicaid (Diamond State Health Plan and fee-for-service) covers Lantus for both type 1 and type 2 diabetes with prior authorization. The PA process typically requires documentation of the diabetes diagnosis (ICD-10 E10.x or E11.x), HbA1c value, failure or contraindication of at least one oral agent (for type 2), and prescriber attestation of medical necessity.

Commercial plans in Delaware commonly tier Lantus to formulary Tier 3, making biosimilar alternatives such as Semglee (insulin glargine-yfgn, FDA-approved as interchangeable in July 2021) [11] or Basaglar (FDA-approved 2015) [12] preferred at lower cost-sharing. If your plan denies Lantus in favor of a biosimilar, the clinical evidence supports biosimilar substitution: a 2022 comparative effectiveness review published in Diabetes Care found no significant difference in HbA1c reduction or hypoglycemia rates between Semglee and Lantus in a pooled analysis of three randomized trials (N=891). [13]

For Delaware Medicaid PA submissions, the standard form requires:

• Patient name, Medicaid ID, and diagnosis code
• Most recent HbA1c result (within 6 months preferred)
• Current diabetes medication list
• Prescriber NPI and DEA number
• Clinical justification for brand Lantus over a biosimilar (if applicable)

PA decisions in Delaware must be issued within 72 hours for urgent requests and within 14 calendar days for standard requests under Delaware Code Title 18, Chapter 33. [14] If denied, prescribers can request a peer-to-peer review call with the plan's medical director within 5 business days of the denial.

Pharmacy Access and Biosimilar Options in Delaware

Every major retail pharmacy chain operating in Delaware stocks Lantus SoloStar 3-mL pens (5 per box, 300 units total) and 10-mL vials. Walmart pharmacies in Delaware stock ReliOn branded regular and NPH insulin over-the-counter, but insulin glargine (Lantus or biosimilar) requires a prescription regardless of concentration.

The cash price of Lantus without insurance averages $300 to $350 per 10-mL vial at Delaware retail pharmacies as of mid-2025. Sanofi's Insulins Valyou Savings Program caps out-of-pocket cost at $99 per 30-day supply for eligible uninsured or underinsured patients. [15]

Semglee is FDA-designated as interchangeable with Lantus, meaning Delaware pharmacists can substitute Semglee without contacting the prescriber, per Delaware Board of Pharmacy regulations aligned with the federal interchangeable biosimilar framework. [11] Rezvoglar (insulin glargine-aglr, FDA-approved 2022) is another interchangeable biosimilar available in Delaware. [16]

503A compounding pharmacies licensed by the Delaware Board of Pharmacy may prepare insulin glargine formulations for individual patients when a commercial product is not clinically suitable, for example patients requiring a concentration other than U-100. Any 503A pharmacy filling a Delaware prescription must hold a current Delaware pharmacy permit and comply with USP Chapter 797 sterile compounding standards. [17]

Mail-order pharmacies licensed to operate in Delaware, including CVS Caremark, Express Scripts, and Optum Rx, fill 90-day supplies of Lantus and biosimilars. A 90-day mail supply typically costs 10 to 25% less than three separate 30-day retail fills depending on plan benefit design.

Transferring an Existing Lantus Prescription to Delaware

Delaware law allows transfer of non-controlled prescription refills between licensed pharmacies across state lines, provided the receiving pharmacy is licensed to dispense in Delaware. Insulin glargine is not a controlled substance, so no special transfer documentation beyond the standard refill authorization is required.

To transfer your Lantus prescription:

1. Contact the Delaware pharmacy where you want to fill the medication.
2. Provide the name, address, and phone number of your current pharmacy.
3. The Delaware pharmacist contacts the out-of-state pharmacy to transfer remaining authorized refills.
4. If refills are exhausted, you will need a new prescription from a Delaware-licensed prescriber (in-person or telehealth).

For patients relocating permanently to Delaware, updating your prescriber to a Delaware-licensed clinician ensures smooth PA renewals and PDMP compliance going forward. Delaware participates in the PMP InterConnect network, so out-of-state controlled-substance history is visible to Delaware prescribers. Insulin glargine is not tracked in the PDMP, so this step is relevant mainly to patients on concurrent controlled medications.

How Long Until I Receive Lantus in Delaware?

Timing depends on pharmacy type and prior authorization status.

Retail pharmacy, insurance approved or cash pay: Most Delaware retail pharmacies fill Lantus same-day or within 24 hours if the drug is in stock. Call ahead to confirm vial or pen inventory, particularly at independent pharmacies in rural Sussex County or Kent County.

Prior authorization required: Expect 24 to 72 hours for urgent PA and up to 14 days for standard PA under Delaware law. [14] Request urgent status from your prescriber if you have fewer than a 3-day supply remaining.

Mail-order pharmacy: Standard delivery takes 3 to 5 business days. Insulin is temperature-sensitive; reputable mail-order pharmacies ship Lantus in insulated packaging with gel packs rated for the delivery window.

Telehealth + same-day fill: A patient who completes a morning telehealth visit with a Delaware-licensed HealthRX provider can receive the e-prescription within 2 hours and pick up Lantus at a local pharmacy the same afternoon, assuming no PA is required.

Cost Reduction Strategies for Lantus in Delaware

Insulin affordability remains a documented access barrier. A 2021 analysis in Health Affairs estimated that 14% of insulin-using adults in the U.S. reported rationing insulin due to cost, with lower-income adults disproportionately affected. [18]

Delaware enacted no state-specific insulin cost cap as of mid-2025, but federal policy changes under the Inflation Reduction Act (IRA) capped Medicare Part D insulin cost-sharing at $35 per month beginning January 2023. [19] Delaware Medicare beneficiaries filling Lantus under Part D pay no more than $35 per 30-day supply.

For non-Medicare patients, strategies include:

• Sanofi Valyou Savings Program: $99/month cap for uninsured/underinsured patients. [15]
• GoodRx or RxSaver coupons: Discounts range from 20 to 45% off retail cash price at Delaware pharmacies.
• Semglee or Rezvoglar biosimilar substitution: Typically 65 to 80% lower cash price than brand Lantus.
• Delaware DHSS Pharmaceutical Assistance Program: State assistance for qualifying low-income residents; income threshold set at 200% of federal poverty level.
• Walmart ReliOn Basaglar: As of 2024, Walmart offers Basaglar KwikPen through its health centers and pharmacy at a reduced private-label price, expanding access in Delaware Walmart locations.

A 2023 JAMA Internal Medicine analysis of insulin pricing found that biosimilar entry reduced net insulin prices by a mean of 22% in markets where at least two biosimilars competed. [20] Delaware patients benefit from that competition given formulary availability of Semglee and Rezvoglar.

Safety Monitoring After Starting Lantus

The FDA label for Lantus identifies hypoglycemia as the most common adverse reaction. [1] Patients should monitor fasting glucose daily during the titration phase and recognize hypoglycemia symptoms: shakiness, sweating, confusion, and heart palpitations at glucose levels generally below 70 mg/dL.

The FDA issued a class-wide label update in 2011 requiring basal insulin labels to address the risk of hypokalemia, which can occur because insulin shifts potassium intracellularly. [1] Patients on loop diuretics or with pre-existing hypokalemia need serum potassium monitoring at baseline and within 1 to 2 weeks of dose escalation.

Injection site reactions occur in a small percentage of patients. Rotating injection sites within the same anatomical region (at least 1 cm from prior injection) reduces lipohypertrophy risk. The ADA recommends formal injection technique training at initiation. [4]

A pooled analysis from three trials (N=2,961) published in Diabetes, Obesity and Metabolism found no significant difference in severe hypoglycemia rates between glargine U-100 and glargine U-300 (Toujeo) over 6 months. [21] Clinicians should note that Lantus U-100 and Toujeo U-300 are not dose-unit-equivalent; converting between them requires explicit dose recalculation.

The FDA Adverse Event Reporting System (FAERS) database lists injection-site pain, edema, and weight gain as the most commonly reported non-hypoglycemic adverse events for insulin glargine since market entry. [22] Weight gain averages 1.5 to 3 kg over the first year of basal insulin therapy per a 2018 meta-analysis in BMJ Open Diabetes Research and Care (N=7,389 across 18 trials). [23]